Skip to main content
. 2019 Sep 30;30(3):177–185. doi: 10.31138/mjr.30.3.177

Figure 1.

Figure 1.

Kaplan-Meier estimate of persistence to Tocilizumab therapy at 6 months of A) the whole cohort and by B) adverse event occurrence, C) response, D) type of therapy, E) remission status.